FDA Approves Regeneron's Gene Therapy to Restore Hearing
Regeneron Pharmaceuticals (NASDAQ: REGN) recently received FDA accelerated approval for Otarmeni, its gene therapy aimed at restoring hearing. Despite this milestone, the company’s stock has declined over 11% year-to-date due in part to falling sales of Eylea and mixed earnings results.
Tickers: $REGN